 Dara Aisner
Concepts (418)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 67 | 2025 | 2531 | 4.850 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 46 | 2025 | 1108 | 3.770 |
Why?
| | Genetic Testing | 9 | 2022 | 457 | 2.210 |
Why?
| | ErbB Receptors | 22 | 2025 | 613 | 2.200 |
Why?
| | Mutation | 41 | 2025 | 3998 | 2.050 |
Why?
| | Pathology, Molecular | 7 | 2019 | 25 | 2.000 |
Why?
| | High-Throughput Nucleotide Sequencing | 15 | 2025 | 541 | 1.890 |
Why?
| | Oncogene Proteins, Fusion | 13 | 2019 | 206 | 1.870 |
Why?
| | Protein Kinase Inhibitors | 26 | 2025 | 914 | 1.730 |
Why?
| | Molecular Diagnostic Techniques | 3 | 2020 | 102 | 1.540 |
Why?
| | Neoplasms | 13 | 2025 | 2701 | 1.360 |
Why?
| | Proto-Oncogene Proteins B-raf | 13 | 2022 | 222 | 1.360 |
Why?
| | Proto-Oncogene Proteins | 17 | 2018 | 623 | 1.350 |
Why?
| | Protein-Tyrosine Kinases | 12 | 2018 | 431 | 1.300 |
Why?
| | Biomarkers, Tumor | 18 | 2024 | 1236 | 1.130 |
Why?
| | Receptor Protein-Tyrosine Kinases | 10 | 2019 | 231 | 1.050 |
Why?
| | DNA, Neoplasm | 3 | 2019 | 158 | 1.050 |
Why?
| | Antineoplastic Agents | 16 | 2024 | 2161 | 1.010 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 11 | 2020 | 263 | 0.990 |
Why?
| | Proto-Oncogene Proteins c-met | 5 | 2019 | 73 | 0.900 |
Why?
| | Drug Resistance, Neoplasm | 13 | 2023 | 800 | 0.900 |
Why?
| | Acrylamides | 5 | 2025 | 58 | 0.800 |
Why?
| | Gene Rearrangement | 13 | 2019 | 152 | 0.790 |
Why?
| | Colorectal Neoplasms | 3 | 2022 | 803 | 0.780 |
Why?
| | Adenocarcinoma | 9 | 2018 | 882 | 0.770 |
Why?
| | Molecular Targeted Therapy | 11 | 2024 | 414 | 0.720 |
Why?
| | Ganglioglioma | 4 | 2014 | 34 | 0.720 |
Why?
| | Brain Neoplasms | 10 | 2018 | 1268 | 0.700 |
Why?
| | DNA Mutational Analysis | 11 | 2020 | 398 | 0.690 |
Why?
| | Aniline Compounds | 4 | 2025 | 102 | 0.670 |
Why?
| | Humans | 125 | 2025 | 138651 | 0.650 |
Why?
| | Precision Medicine | 4 | 2018 | 419 | 0.640 |
Why?
| | Adenocarcinoma, Mucinous | 2 | 2022 | 73 | 0.630 |
Why?
| | Pyrazoles | 10 | 2018 | 429 | 0.620 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2020 | 94 | 0.620 |
Why?
| | Neoplasms, Muscle Tissue | 1 | 2019 | 3 | 0.620 |
Why?
| | Immunohistochemistry | 10 | 2023 | 1732 | 0.610 |
Why?
| | Receptors, Nerve Growth Factor | 1 | 2019 | 18 | 0.610 |
Why?
| | Biological Products | 1 | 2022 | 229 | 0.600 |
Why?
| | Prognosis | 14 | 2024 | 4015 | 0.600 |
Why?
| | Astrocytoma | 3 | 2015 | 127 | 0.590 |
Why?
| | Neoplasm Metastasis | 10 | 2024 | 668 | 0.590 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 7 | 2024 | 1748 | 0.580 |
Why?
| | Insurance Coverage | 1 | 2020 | 233 | 0.580 |
Why?
| | In Situ Hybridization, Fluorescence | 13 | 2019 | 309 | 0.550 |
Why?
| | Laboratory Proficiency Testing | 2 | 2023 | 8 | 0.550 |
Why?
| | Computational Biology | 4 | 2023 | 650 | 0.520 |
Why?
| | RNA | 5 | 2019 | 928 | 0.480 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2023 | 527 | 0.470 |
Why?
| | Neoplasm Staging | 13 | 2024 | 1376 | 0.440 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2016 | 115 | 0.430 |
Why?
| | Smoking | 3 | 2018 | 1607 | 0.420 |
Why?
| | Pyrimidines | 6 | 2025 | 476 | 0.420 |
Why?
| | ras Proteins | 5 | 2015 | 149 | 0.420 |
Why?
| | Aged, 80 and over | 18 | 2025 | 7683 | 0.420 |
Why?
| | Pyridines | 8 | 2016 | 498 | 0.410 |
Why?
| | Mesothelioma | 2 | 2024 | 45 | 0.400 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2022 | 1065 | 0.390 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2014 | 201 | 0.380 |
Why?
| | Aged | 32 | 2025 | 24182 | 0.370 |
Why?
| | Laboratories | 3 | 2025 | 108 | 0.360 |
Why?
| | Male | 52 | 2025 | 68216 | 0.350 |
Why?
| | Female | 53 | 2025 | 73913 | 0.350 |
Why?
| | Telomerase | 7 | 2002 | 248 | 0.350 |
Why?
| | S100 Proteins | 2 | 2014 | 37 | 0.350 |
Why?
| | Middle Aged | 40 | 2025 | 33792 | 0.340 |
Why?
| | Neoadjuvant Therapy | 3 | 2024 | 409 | 0.340 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2014 | 417 | 0.340 |
Why?
| | Pleural Neoplasms | 2 | 2024 | 25 | 0.340 |
Why?
| | Genomics | 4 | 2023 | 804 | 0.320 |
Why?
| | Sulfones | 3 | 2015 | 110 | 0.310 |
Why?
| | Medical Oncology | 4 | 2025 | 303 | 0.300 |
Why?
| | Glycine | 3 | 2015 | 176 | 0.300 |
Why?
| | Curriculum | 1 | 2016 | 1005 | 0.300 |
Why?
| | Early Detection of Cancer | 2 | 2019 | 432 | 0.300 |
Why?
| | Adult | 35 | 2025 | 38296 | 0.280 |
Why?
| | Adrenal Gland Neoplasms | 2 | 2022 | 88 | 0.270 |
Why?
| | Head and Neck Neoplasms | 3 | 2019 | 554 | 0.270 |
Why?
| | Neoplasms, Multiple Primary | 2 | 2022 | 58 | 0.270 |
Why?
| | Oncogene Fusion | 2 | 2019 | 11 | 0.260 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 4 | 2022 | 98 | 0.260 |
Why?
| | Indoles | 5 | 2025 | 411 | 0.260 |
Why?
| | Gene Dosage | 2 | 2018 | 142 | 0.260 |
Why?
| | Treatment Outcome | 12 | 2024 | 10938 | 0.260 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2018 | 53 | 0.260 |
Why?
| | Exons | 5 | 2019 | 355 | 0.250 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2018 | 191 | 0.250 |
Why?
| | Melanoma | 2 | 2020 | 766 | 0.250 |
Why?
| | Survival Analysis | 5 | 2025 | 1313 | 0.250 |
Why?
| | Genetic Predisposition to Disease | 6 | 2019 | 2368 | 0.240 |
Why?
| | Phosphatidylinositol 3-Kinases | 4 | 2023 | 369 | 0.240 |
Why?
| | Oncogenes | 3 | 2016 | 118 | 0.240 |
Why?
| | Thymus Neoplasms | 1 | 2025 | 25 | 0.230 |
Why?
| | Sodium-Phosphate Cotransporter Proteins, Type IIb | 3 | 2015 | 8 | 0.230 |
Why?
| | Thymoma | 1 | 2025 | 36 | 0.230 |
Why?
| | Receptor, ErbB-2 | 4 | 2022 | 355 | 0.230 |
Why?
| | Pemetrexed | 1 | 2024 | 33 | 0.220 |
Why?
| | Epithelioid Cells | 2 | 2015 | 8 | 0.220 |
Why?
| | Immunotherapy | 5 | 2022 | 631 | 0.220 |
Why?
| | Fetomaternal Transfusion | 1 | 2023 | 11 | 0.210 |
Why?
| | Sensitivity and Specificity | 5 | 2019 | 1958 | 0.200 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2019 | 646 | 0.200 |
Why?
| | Choriocarcinoma | 1 | 2022 | 9 | 0.200 |
Why?
| | Endodermal Sinus Tumor | 1 | 2022 | 9 | 0.200 |
Why?
| | Cell Line, Tumor | 11 | 2018 | 3406 | 0.190 |
Why?
| | Tertiary Care Centers | 1 | 2023 | 170 | 0.190 |
Why?
| | Pathologists | 2 | 2023 | 18 | 0.190 |
Why?
| | Young Adult | 13 | 2024 | 13322 | 0.180 |
Why?
| | Biopsy, Fine-Needle | 2 | 2012 | 68 | 0.180 |
Why?
| | Goals | 1 | 2023 | 174 | 0.180 |
Why?
| | Gene Fusion | 2 | 2018 | 26 | 0.180 |
Why?
| | Patient Selection | 4 | 2018 | 692 | 0.180 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2022 | 36 | 0.180 |
Why?
| | Cell Proliferation | 7 | 2017 | 2474 | 0.180 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2022 | 78 | 0.180 |
Why?
| | Hematologic Neoplasms | 1 | 2023 | 159 | 0.180 |
Why?
| | United States | 10 | 2025 | 15018 | 0.170 |
Why?
| | Graft vs Host Disease | 1 | 2023 | 252 | 0.170 |
Why?
| | Biopsy | 4 | 2018 | 1093 | 0.170 |
Why?
| | Carbazoles | 1 | 2021 | 56 | 0.170 |
Why?
| | Endometrial Neoplasms | 1 | 2023 | 200 | 0.170 |
Why?
| | Trastuzumab | 1 | 2021 | 97 | 0.170 |
Why?
| | Pheochromocytoma | 1 | 2022 | 57 | 0.170 |
Why?
| | Combined Modality Therapy | 4 | 2018 | 1237 | 0.170 |
Why?
| | Meningioma | 1 | 2022 | 94 | 0.170 |
Why?
| | Glioblastoma | 2 | 2015 | 341 | 0.170 |
Why?
| | Laboratories, Hospital | 1 | 2020 | 12 | 0.170 |
Why?
| | DNA Copy Number Variations | 5 | 2025 | 178 | 0.160 |
Why?
| | Pathology, Clinical | 2 | 2017 | 29 | 0.160 |
Why?
| | Government Regulation | 1 | 2020 | 51 | 0.160 |
Why?
| | GTP Phosphohydrolases | 1 | 2020 | 94 | 0.160 |
Why?
| | Piperidines | 1 | 2021 | 215 | 0.160 |
Why?
| | Stakeholder Participation | 1 | 2020 | 79 | 0.150 |
Why?
| | Costs and Cost Analysis | 1 | 2020 | 220 | 0.150 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2018 | 333 | 0.150 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 2 | 2017 | 55 | 0.150 |
Why?
| | Chromosome Aberrations | 2 | 2019 | 158 | 0.150 |
Why?
| | Genes, erbB-2 | 2 | 2015 | 28 | 0.150 |
Why?
| | Smad4 Protein | 1 | 2019 | 35 | 0.150 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2019 | 53 | 0.150 |
Why?
| | Genetic Heterogeneity | 1 | 2019 | 59 | 0.150 |
Why?
| | Multigene Family | 1 | 2019 | 201 | 0.150 |
Why?
| | Breast Neoplasms, Male | 1 | 2018 | 29 | 0.140 |
Why?
| | Genetic Markers | 1 | 2019 | 345 | 0.140 |
Why?
| | Pregnancy Complications | 1 | 2023 | 535 | 0.140 |
Why?
| | Pyridazines | 1 | 2018 | 57 | 0.140 |
Why?
| | Database Management Systems | 1 | 2018 | 51 | 0.140 |
Why?
| | Cell Cycle Proteins | 4 | 2015 | 615 | 0.140 |
Why?
| | Piperazines | 2 | 2018 | 349 | 0.140 |
Why?
| | Gene Frequency | 1 | 2019 | 504 | 0.140 |
Why?
| | Genetic Association Studies | 1 | 2019 | 373 | 0.140 |
Why?
| | Thromboembolism | 1 | 2018 | 117 | 0.140 |
Why?
| | Quinazolines | 3 | 2014 | 250 | 0.140 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2018 | 38 | 0.140 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2018 | 254 | 0.140 |
Why?
| | Smokers | 1 | 2018 | 141 | 0.130 |
Why?
| | Skin Neoplasms | 2 | 2020 | 854 | 0.130 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2018 | 137 | 0.130 |
Why?
| | Imidazoles | 1 | 2018 | 240 | 0.130 |
Why?
| | Gene Deletion | 1 | 2019 | 391 | 0.130 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2024 | 633 | 0.130 |
Why?
| | Medical Informatics | 1 | 2018 | 101 | 0.130 |
Why?
| | Intraoperative Care | 1 | 2017 | 62 | 0.130 |
Why?
| | Chloroquine | 1 | 2017 | 52 | 0.130 |
Why?
| | Retrospective Studies | 11 | 2025 | 15860 | 0.130 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 216 | 0.130 |
Why?
| | Ovarian Neoplasms | 1 | 2022 | 575 | 0.130 |
Why?
| | Small Molecule Libraries | 1 | 2017 | 94 | 0.120 |
Why?
| | Pleural Effusion, Malignant | 1 | 2016 | 12 | 0.120 |
Why?
| | Coculture Techniques | 1 | 2017 | 241 | 0.120 |
Why?
| | Disease Progression | 6 | 2024 | 2734 | 0.120 |
Why?
| | Carcinogenesis | 1 | 2017 | 215 | 0.120 |
Why?
| | Clinical Decision-Making | 1 | 2019 | 332 | 0.120 |
Why?
| | Sulfonamides | 2 | 2017 | 508 | 0.120 |
Why?
| | RNA, Messenger | 4 | 2018 | 2817 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2016 | 68 | 0.120 |
Why?
| | Immunity, Humoral | 1 | 2016 | 117 | 0.120 |
Why?
| | Codon | 1 | 2016 | 92 | 0.120 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2016 | 79 | 0.120 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2018 | 204 | 0.120 |
Why?
| | Protein Kinases | 1 | 2017 | 308 | 0.120 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2016 | 104 | 0.120 |
Why?
| | Peritoneal Neoplasms | 1 | 2016 | 98 | 0.120 |
Why?
| | Oncogene Proteins | 1 | 2015 | 58 | 0.120 |
Why?
| | Clinical Laboratory Techniques | 1 | 2016 | 94 | 0.110 |
Why?
| | Fatal Outcome | 1 | 2016 | 311 | 0.110 |
Why?
| | Signal Transduction | 5 | 2017 | 5091 | 0.110 |
Why?
| | Amino Acid Substitution | 1 | 2016 | 309 | 0.110 |
Why?
| | Practice Guidelines as Topic | 2 | 2019 | 1551 | 0.110 |
Why?
| | Hamartoma | 1 | 2015 | 22 | 0.110 |
Why?
| | Immunity, Cellular | 1 | 2016 | 270 | 0.110 |
Why?
| | Sequence Analysis, RNA | 1 | 2017 | 452 | 0.110 |
Why?
| | Pharmacogenetics | 1 | 2016 | 165 | 0.110 |
Why?
| | Medicare | 1 | 2020 | 785 | 0.110 |
Why?
| | Genetic Variation | 1 | 2019 | 1003 | 0.110 |
Why?
| | Meningeal Carcinomatosis | 1 | 2014 | 8 | 0.110 |
Why?
| | Spinal Cord Neoplasms | 1 | 2014 | 38 | 0.110 |
Why?
| | Autophagy | 1 | 2017 | 286 | 0.110 |
Why?
| | Health Care Surveys | 1 | 2016 | 563 | 0.110 |
Why?
| | Speech Disorders | 1 | 2014 | 31 | 0.110 |
Why?
| | Paresis | 1 | 2014 | 30 | 0.110 |
Why?
| | Deoxycytidine | 1 | 2015 | 193 | 0.110 |
Why?
| | Multimodal Imaging | 1 | 2015 | 117 | 0.110 |
Why?
| | Alternative Splicing | 3 | 2017 | 227 | 0.110 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2015 | 317 | 0.110 |
Why?
| | Receptor, trkA | 1 | 2013 | 16 | 0.110 |
Why?
| | Liver Neoplasms | 3 | 2015 | 761 | 0.100 |
Why?
| | Membrane Proteins | 1 | 2020 | 1153 | 0.100 |
Why?
| | Polymerase Chain Reaction | 2 | 2014 | 1049 | 0.100 |
Why?
| | Tumor Cells, Cultured | 5 | 2019 | 949 | 0.100 |
Why?
| | Wnt Signaling Pathway | 1 | 2015 | 196 | 0.100 |
Why?
| | Intracranial Hemorrhages | 1 | 2014 | 89 | 0.100 |
Why?
| | Microscopy, Electron | 1 | 2014 | 438 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2021 | 2045 | 0.100 |
Why?
| | Positron-Emission Tomography | 1 | 2015 | 302 | 0.100 |
Why?
| | Lung Transplantation | 1 | 2016 | 330 | 0.100 |
Why?
| | Brain Stem Neoplasms | 1 | 2013 | 83 | 0.100 |
Why?
| | Serine Endopeptidases | 1 | 2013 | 120 | 0.100 |
Why?
| | Headache | 1 | 2014 | 147 | 0.100 |
Why?
| | Sarcoma | 1 | 2015 | 189 | 0.100 |
Why?
| | Graft Rejection | 1 | 2016 | 577 | 0.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2017 | 981 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2019 | 1388 | 0.100 |
Why?
| | Societies, Medical | 4 | 2018 | 830 | 0.100 |
Why?
| | Bone Neoplasms | 1 | 2015 | 249 | 0.100 |
Why?
| | Microtubule-Associated Proteins | 1 | 2013 | 197 | 0.090 |
Why?
| | Tissue Fixation | 1 | 2012 | 37 | 0.090 |
Why?
| | Recombinant Fusion Proteins | 2 | 2013 | 662 | 0.090 |
Why?
| | Gene Amplification | 3 | 2019 | 103 | 0.090 |
Why?
| | Predictive Value of Tests | 2 | 2015 | 2039 | 0.090 |
Why?
| | Mutation Rate | 1 | 2011 | 31 | 0.090 |
Why?
| | Lung | 4 | 2015 | 4086 | 0.090 |
Why?
| | Algorithms | 1 | 2019 | 1718 | 0.090 |
Why?
| | Translocation, Genetic | 1 | 2012 | 108 | 0.090 |
Why?
| | Education, Medical, Graduate | 1 | 2016 | 490 | 0.090 |
Why?
| | Interdisciplinary Communication | 1 | 2012 | 187 | 0.090 |
Why?
| | Tomography, X-Ray Computed | 3 | 2018 | 2703 | 0.090 |
Why?
| | Clinical Trials as Topic | 3 | 2025 | 1033 | 0.090 |
Why?
| | Specimen Handling | 1 | 2012 | 182 | 0.080 |
Why?
| | Epithelial Cells | 1 | 2017 | 1102 | 0.080 |
Why?
| | Teratoma | 1 | 2011 | 118 | 0.080 |
Why?
| | Rhabdoid Tumor | 1 | 2011 | 99 | 0.080 |
Why?
| | DNA-Binding Proteins | 6 | 2011 | 1476 | 0.080 |
Why?
| | Terminology as Topic | 1 | 2012 | 247 | 0.080 |
Why?
| | Prospective Studies | 2 | 2023 | 7639 | 0.080 |
Why?
| | Genome, Human | 1 | 2012 | 418 | 0.080 |
Why?
| | Immunoenzyme Techniques | 3 | 2015 | 209 | 0.080 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2019 | 865 | 0.080 |
Why?
| | Breast Neoplasms | 1 | 2022 | 2294 | 0.080 |
Why?
| | Phosphorylation | 1 | 2014 | 1770 | 0.080 |
Why?
| | Erlotinib Hydrochloride | 3 | 2014 | 69 | 0.080 |
Why?
| | Survival Rate | 4 | 2019 | 1932 | 0.080 |
Why?
| | Catheter Ablation | 1 | 2012 | 332 | 0.080 |
Why?
| | Disease-Free Survival | 3 | 2016 | 704 | 0.080 |
Why?
| | Leukemia-Lymphoma, Adult T-Cell | 1 | 2008 | 14 | 0.070 |
Why?
| | Telomere | 3 | 2000 | 276 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-ret | 2 | 2018 | 34 | 0.070 |
Why?
| | Diagnosis, Differential | 1 | 2012 | 1496 | 0.070 |
Why?
| | beta Catenin | 2 | 2023 | 252 | 0.070 |
Why?
| | Maximum Tolerated Dose | 2 | 2021 | 204 | 0.070 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2024 | 661 | 0.070 |
Why?
| | Follow-Up Studies | 4 | 2021 | 5160 | 0.070 |
Why?
| | Heart Neoplasms | 1 | 2008 | 56 | 0.070 |
Why?
| | DNA | 1 | 2014 | 1449 | 0.070 |
Why?
| | Pancreatic Neoplasms | 1 | 2015 | 856 | 0.070 |
Why?
| | Adolescent | 6 | 2019 | 21528 | 0.060 |
Why?
| | Reproducibility of Results | 3 | 2019 | 3311 | 0.060 |
Why?
| | Workflow | 2 | 2017 | 164 | 0.060 |
Why?
| | Eye Neoplasms | 1 | 2005 | 28 | 0.060 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2025 | 48 | 0.060 |
Why?
| | Internship and Residency | 1 | 2016 | 1176 | 0.060 |
Why?
| | Mental Disorders | 1 | 2014 | 1091 | 0.060 |
Why?
| | Myasthenia Gravis | 1 | 2025 | 22 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2025 | 2143 | 0.050 |
Why?
| | Pleura | 1 | 2024 | 23 | 0.050 |
Why?
| | Immunophenotyping | 1 | 2005 | 326 | 0.050 |
Why?
| | Administration, Oral | 2 | 2018 | 789 | 0.050 |
Why?
| | Induction Chemotherapy | 1 | 2024 | 78 | 0.050 |
Why?
| | DNA Polymerase II | 1 | 2023 | 35 | 0.050 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2023 | 33 | 0.050 |
Why?
| | Peritoneum | 1 | 2023 | 43 | 0.050 |
Why?
| | Genes, ras | 2 | 2015 | 94 | 0.050 |
Why?
| | DNA Mismatch Repair | 1 | 2023 | 47 | 0.050 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2015 | 349 | 0.050 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 2 | 2013 | 35 | 0.050 |
Why?
| | Leukocyte Count | 1 | 2024 | 327 | 0.050 |
Why?
| | Blotting, Western | 4 | 2015 | 1229 | 0.050 |
Why?
| | Carcinoma, Endometrioid | 1 | 2022 | 50 | 0.050 |
Why?
| | Cell Cycle | 2 | 2012 | 598 | 0.050 |
Why?
| | Cell Survival | 2 | 2017 | 1129 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3642 | 0.050 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2002 | 122 | 0.040 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2013 | 365 | 0.040 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2002 | 277 | 0.040 |
Why?
| | Gene Expression Profiling | 2 | 2017 | 1755 | 0.040 |
Why?
| | Models, Molecular | 2 | 2018 | 1598 | 0.040 |
Why?
| | Base Sequence | 3 | 2017 | 2182 | 0.040 |
Why?
| | Standard of Care | 1 | 2020 | 78 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2002 | 463 | 0.040 |
Why?
| | HSP90 Heat-Shock Proteins | 1 | 1999 | 46 | 0.040 |
Why?
| | Time Factors | 3 | 2020 | 6877 | 0.040 |
Why?
| | Catalytic Domain | 4 | 2000 | 228 | 0.040 |
Why?
| | Fetus | 1 | 2023 | 801 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2023 | 668 | 0.040 |
Why?
| | Cell Nucleus | 1 | 2002 | 611 | 0.040 |
Why?
| | Sequence Deletion | 2 | 2014 | 184 | 0.040 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2018 | 34 | 0.040 |
Why?
| | Aurora Kinase A | 1 | 2018 | 57 | 0.040 |
Why?
| | Cohort Studies | 2 | 2019 | 5729 | 0.040 |
Why?
| | Cell Line | 4 | 2012 | 2874 | 0.040 |
Why?
| | Proto-Oncogenes | 1 | 2018 | 28 | 0.040 |
Why?
| | RNA, Untranslated | 1 | 1999 | 124 | 0.040 |
Why?
| | Phthalazines | 1 | 2018 | 45 | 0.030 |
Why?
| | Nausea | 1 | 2018 | 112 | 0.030 |
Why?
| | Cetuximab | 1 | 2018 | 98 | 0.030 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2017 | 27 | 0.030 |
Why?
| | Breast | 1 | 2018 | 158 | 0.030 |
Why?
| | Diarrhea | 1 | 2018 | 184 | 0.030 |
Why?
| | Quality Control | 1 | 2017 | 169 | 0.030 |
Why?
| | Child | 5 | 2015 | 21883 | 0.030 |
Why?
| | A549 Cells | 1 | 2017 | 72 | 0.030 |
Why?
| | Molecular Sequence Data | 3 | 2013 | 2928 | 0.030 |
Why?
| | Pathology, Surgical | 1 | 2016 | 9 | 0.030 |
Why?
| | Structure-Activity Relationship | 1 | 2018 | 569 | 0.030 |
Why?
| | Fatigue | 1 | 2018 | 337 | 0.030 |
Why?
| | Centrosome | 1 | 2016 | 71 | 0.030 |
Why?
| | Drug Synergism | 1 | 2017 | 371 | 0.030 |
Why?
| | Carcinoma | 2 | 2012 | 230 | 0.030 |
Why?
| | Dual Specificity Phosphatase 6 | 1 | 2015 | 6 | 0.030 |
Why?
| | Genes, erbB-1 | 1 | 2015 | 18 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2002 | 1462 | 0.030 |
Why?
| | Mice, Nude | 1 | 2017 | 689 | 0.030 |
Why?
| | Lamin Type A | 1 | 2015 | 47 | 0.030 |
Why?
| | Cell Line, Transformed | 3 | 2000 | 145 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2015 | 132 | 0.030 |
Why?
| | Child, Preschool | 3 | 2015 | 11130 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1497 | 0.030 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2015 | 75 | 0.030 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2015 | 94 | 0.030 |
Why?
| | Consensus | 1 | 2018 | 678 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 732 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 827 | 0.030 |
Why?
| | Respiratory Mucosa | 1 | 2017 | 321 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2015 | 187 | 0.030 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2015 | 144 | 0.030 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2015 | 385 | 0.030 |
Why?
| | Recurrence | 1 | 2017 | 1102 | 0.030 |
Why?
| | Microdissection | 1 | 2013 | 15 | 0.030 |
Why?
| | Epidermal Growth Factor | 1 | 2013 | 176 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 769 | 0.030 |
Why?
| | Animals | 5 | 2019 | 37309 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2018 | 817 | 0.020 |
Why?
| | Disease Management | 1 | 2017 | 620 | 0.020 |
Why?
| | Syndecan-4 | 1 | 2012 | 6 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2015 | 445 | 0.020 |
Why?
| | Papillomaviridae | 1 | 2013 | 133 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 1486 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2015 | 458 | 0.020 |
Why?
| | Transcriptome | 1 | 2018 | 970 | 0.020 |
Why?
| | Bone and Bones | 1 | 2015 | 317 | 0.020 |
Why?
| | SMARCB1 Protein | 1 | 2011 | 30 | 0.020 |
Why?
| | Hyperglycemia | 1 | 2015 | 347 | 0.020 |
Why?
| | Incidence | 1 | 2018 | 2830 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2012 | 398 | 0.020 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2011 | 126 | 0.020 |
Why?
| | Bronchoscopy | 1 | 2012 | 219 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 2012 | 326 | 0.020 |
Why?
| | Mice | 2 | 2019 | 17848 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2013 | 430 | 0.020 |
Why?
| | Pregnancy | 1 | 2023 | 6836 | 0.020 |
Why?
| | Infant | 2 | 2015 | 9565 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2014 | 850 | 0.020 |
Why?
| | Cognition Disorders | 1 | 2014 | 509 | 0.020 |
Why?
| | Reticulocytes | 2 | 1999 | 17 | 0.020 |
Why?
| | Retroviridae | 2 | 2000 | 102 | 0.020 |
Why?
| | Hypertension | 1 | 2018 | 1253 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2012 | 864 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2017 | 4175 | 0.020 |
Why?
| | Sex Factors | 1 | 2015 | 2058 | 0.020 |
Why?
| | Papillomavirus Infections | 1 | 2013 | 378 | 0.020 |
Why?
| | Leukemic Infiltration | 1 | 2008 | 7 | 0.020 |
Why?
| | Genetic Vectors | 2 | 2000 | 335 | 0.020 |
Why?
| | Human T-lymphotropic virus 1 | 1 | 2008 | 28 | 0.020 |
Why?
| | DNA Primers | 2 | 1999 | 509 | 0.020 |
Why?
| | Rabbits | 2 | 1999 | 766 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2015 | 2838 | 0.020 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2008 | 130 | 0.020 |
Why?
| | In Vitro Techniques | 2 | 1999 | 1093 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2016 | 1983 | 0.020 |
Why?
| | Phenotype | 1 | 2015 | 3160 | 0.020 |
Why?
| | Apoptosis | 1 | 2015 | 2558 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 4111 | 0.010 |
Why?
| | Fibroblasts | 2 | 2000 | 1002 | 0.010 |
Why?
| | Transcription Factors | 1 | 2011 | 1707 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2013 | 6143 | 0.010 |
Why?
| | Peptide Chain Termination, Translational | 1 | 2000 | 9 | 0.010 |
Why?
| | Fetal Proteins | 1 | 2000 | 15 | 0.010 |
Why?
| | Genes, Dominant | 1 | 2000 | 97 | 0.010 |
Why?
| | Chromosomes, Human | 1 | 2000 | 45 | 0.010 |
Why?
| | Fibrosarcoma | 1 | 2000 | 21 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2000 | 276 | 0.010 |
Why?
| | Protein Subunits | 1 | 2000 | 242 | 0.010 |
Why?
| | Quinones | 1 | 1999 | 9 | 0.010 |
Why?
| | RNA-Directed DNA Polymerase | 1 | 1999 | 34 | 0.010 |
Why?
| | Lactams, Macrocyclic | 1 | 1999 | 49 | 0.010 |
Why?
| | Benzoquinones | 1 | 1999 | 48 | 0.010 |
Why?
| | Transfection | 1 | 2000 | 942 | 0.010 |
Why?
| | Cyclosporine | 1 | 1999 | 268 | 0.010 |
Why?
| | Carcinoma, Renal Cell | 1 | 2000 | 212 | 0.010 |
Why?
| | Half-Life | 1 | 1997 | 147 | 0.010 |
Why?
| | Molecular Chaperones | 1 | 1999 | 193 | 0.010 |
Why?
| | Neoplasm Proteins | 1 | 2000 | 433 | 0.010 |
Why?
| | RNA, Long Noncoding | 1 | 1999 | 173 | 0.010 |
Why?
| | Adenosine Triphosphate | 1 | 1999 | 489 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 1999 | 1358 | 0.010 |
Why?
| | Skin | 1 | 2000 | 753 | 0.010 |
Why?
| | Flow Cytometry | 1 | 1997 | 1197 | 0.010 |
Why?
| | Prostatic Neoplasms | 1 | 2000 | 1048 | 0.010 |
Why?
|
|
Aisner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|